MDTMedtronicGood · Earnings beat
Strong full-year results, "highest annual revenue growth in 10 years."
Q4 revenue $9.8B, up about 10%, and earnings came in ahead of the company's own guidance. A clear beat on both sales and profit.
Dated & window events come from knowledge/calendar.md, synced from the MarketBeat FDA calendar and filtered to the watchlist by ticker. MarketBeat is an aggregator, so per the project rule "primary beats aggregator" every row is a discovery lead, marked unconfirmed until checked against the company's 8-K / press release or an FDA page. No row asserts a date as fact. Last synced 2026-06-07 (13 watchlist matches, 0 confirmed).
Trial activity comes from the trials table in the DuckDB warehouse, loaded from ClinicalTrials.gov — a primary source. Those rows are facts. A completion or status change is a pre-readout signal, not a result.
What this is not: there is no expected price move, entry/exit timing, or recommendation anywhere on this page. Gekko is an information and understanding tool. It does not give buy / sell / hold calls and never executes or simulates trades.
Q4 revenue $9.8B, up about 10%, and earnings came in ahead of the company's own guidance. A clear beat on both sales and profit.
Quarterly revenue $882.9M, up 16%. The company says it exceeded guidance on every metric and lifted its full-year outlook.
Note: some headlines around the AI rollout were mixed, but that is share-price chatter, not the underlying numbers.
The green light lets dosing start in the second half of 2026. This is permission to begin a study, not efficacy data, so it is an early-stage positive.
Forward progress after an earlier incomplete review, but a re-filing is a step in the process, not an approval. Watch for the new FDA decision date.
The government opting out generally lowers the threat, but the person who brought the case can still pursue it alone. Removes one overhang, not all of it.
The direction looks favorable from the wording, but this is a small, early, investigator-run study. A weak signal. Do not over-weight it.
The company says it has grounds to appeal, which signals the ruling went against it. A legal overhang, and the outcome is not final.
It is exploring a merger, sale, or licensing deal while also cutting costs. Together that reads as a company under pressure. A sale could carry a premium, but the combination skews negative. Flagged for a human look.
This starts a compliance clock with delisting risk if the price does not recover within the allowed window.
A follow-up to an earlier deficiency notice from February 2026. Delisting risk if not cured in time.
One Class I recall (May 13) plus two lesser Class II actions (manipulator screws, frayed instrument cables). The Class I item is the one to check.
One Class I recall (May 6) plus a Class II device upgrade (May 13). The Class I item warrants a closer look.
Sterile-barrier breach, an infusion-pump app software issue, a therapy risk, and MiniMed pumps. Note: this offsets Medtronic's strong earnings above, so weigh both sides.
Two actions in a single day. The full scope is not yet quantified.
Sterile-seal failures, a tourniquet cuff detachment, and a surgical-light mount. All Class II.
The theft is operational and reputational, not a quality recall. Both are minor.
Data-quality note. An apparent "MIST" recall was a name collision with an unrelated Italian diagnostics firm, not Milestone Pharmaceuticals. It was dropped, and the name-matcher is being watched.
A terminated early trial can be a strategic choice or a setback. The reason is not captured in the feed, so this one genuinely needs a look. Separately, another program (CTX310) is recruiting normally.
NKTR (Nektar) — Neutral. Rezpeg Phase 2b in atopic dermatitis moved to active, not recruiting (Jun 4).
KURA (Kura Oncology) — Neutral. Ziftomenib Phase 3 recruiting (Jun 3); an earlier combination study marked completed (Jun 5).
GILD (Gilead) — Neutral. Several lung-cancer studies moved to active, not recruiting (Jun 1–2).
NVO (Novo Nordisk) — Neutral. A cluster of semaglutide / CagriSema Phase 3 studies marked completed in May. Completion is not results, but readouts tend to follow.
The items below are unfinished, ambiguous, or high-stakes. They are flagged for you to dig into, not resolved here.
Annual-meeting filings (voting results, equity-plan approvals) — UNH, SRPT, PTCT, NKTR, RPRX, GKOS, KYTX, BMRN, KURA, PACB, CRSP, CERS, SRRK, ZVRA. Routine governance. CRSP also filed a bylaw amendment.
Presentation / disclosure filings — CRDF, FOCL, HCAT. HCAT also filed a material agreement worth a follow-up read (see above).
Foreign-ADR check (RHHBY, TERN) — nothing in-window that rises to a primary-source event.
Feeds pulled this run: SEC EDGAR 8-K (124 names, in parallel), FDA RSS x3 (press, MedWatch, recalls, de-duplicated), openFDA enforcement (drug + device, last 60 days), Finnhub company-news (37 targeted names), and ClinicalTrials.gov status changes (flagged names, last 30 days). The full data layer ran in under a minute.
Classification follows the project glossary, not surface tone. 8-K item codes came from the EDGAR feed; full filings were read only for flagged, material names.
Finnhub is a discovery layer only. Nothing entered as fact without a primary source, and its loose date window was re-filtered by each item's own timestamp.
Known limits: openFDA lags real FDA actions and its firm names can collide with watchlist names (see the dropped MIST case). Catalyst dates such as PDUFA decisions and trial readouts are not in the source export, so forward-timing context is limited.